The study involves taking pectin fibre at increasing doses ranging from 5g, 10g and 15g for a total period of 6 weeks with the increase every 2 weeks. Study subjects will be healthy volunteers recruited from the University and local population and will be asked to attend the laboratory on 4 occasions; at the start of the intervention and every 2 weeks, at the end of each dosing period. At each study visit (\~3hrs), participants will be asked to provide a stool and blood sample and will have blood pressure measured. In the week before each study visit, participants will record their food intake.
The study aims to assess the optimal dosage of pectin required to see beneficial effects on inflammation and gut microbiome composition. 15 healthy, non-obese volunteers will be recruited following a successful medical screening. Between recruitment and first study visit, and at the end of each dosing period (before each study visit), participants will be asked to complete a dietary record (4 days), to collect a stool sample on the day before the study visit and to fast from midnight the night before this visit. At both study visits, participants will have weight, hip/waist circumference and blood pressure measured. They will be asked to complete some questionnaires. After completion of the first study day, participants will be provided with the required dosage of pectin for the 2-week dosing period. They will be given the required doses of pectin portioned in individual sachets, with instructions to add the contents of one sachet a day to juice, smoothies or water and to consume immediately. Study visits will be scheduled at the end of every 2-weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
15
15 individuals were provided with increasing doses of pectin: 5g for 2 weeks 10g for 2 weeks 15 for 2 weeks
University of Nottingham
Nottingham, United Kingdom
Change in microbiome profile
Change in microbiome profile, assessed using 16s RNA sequencing analysis of faecal samples provided at the start (pre-intervention) and end of every dosing period (i.e. 2 weeks)
Time frame: 6 weeks
Change in inflammatory profile
Change in circulating markers of inflammation measured by ELISAs in serum samples collected at the start (pre-intervention) and end of every dosing period (i.e. 2 weeks).
Time frame: 6 weeks
Changes in short chain fatty acids (SCFAs)
Change in serum SCFAs measured by mass spectrometry at the start (pre-intervention) and end of every dosing period (i.e. 2 weeks).
Time frame: 6 weeks
Change in systolic blood pressure (lying to standing) pre intervention
Change in systolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at pre-intervention study visit.
Time frame: 6 weeks
Dose response change in Short Form Health Survey (SF36) Questionnaire aggregated normalised 'physical' score
Change in 'SF36' Questionnaire aggregated 'physical' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better physical wellbeing; measured at the start and the end of each dosing period
Time frame: 6 weeks
Dose response change in Short Form Health Survey (SF36) Questionnaire aggregated normalised 'mental' score
Change in 'SF36' Questionnaire aggregated 'mental' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better physical wellbeing; measured at the start and the end of each dosing period
Time frame: 6 weeks
Dose response change in Pittsburgh Sleep Quality Index (PSQI)
Change in PSQI score (min score 0, max 21), measured at the start and the end of each dosing period, with higher score indicating poorer sleep quality
Time frame: 6 weeks
Dose response change in Hospital Anxiety and Depression scores (HADS)
Change in anxiety score (min 0, max 3 which higher scores indicating higher anxiety like symptoms) and depression scores (min 3, max 0 which lower scores indicating higher depressive like symptoms), measured at the start and at the end of each dosing period
Time frame: 6 weeks
Change in systolic blood pressure (lying to standing) post every dosing period
Change in systolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at the end of each dosing period (every 2 weeks)
Time frame: 6 weeks
Change in diastolic blood pressure (lying to standing) post every dosing period
Change in diastolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at the end of each dosing period (every 2 weeks)
Time frame: 6 weeks
Change in diastolic blood pressure (lying to standing) at pre intervention study visit
Change in diastolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), pre intervention
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.